Multiparametric MRI and Radiomics to Predict HER2-Low Cancer: The Potential Therapeutic Impact-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multiparametric MRI and Radiomics to Predict HER2-Low Cancer: The Potential Therapeutic Impact

Published:2023-08-01 Issue:2 Volume:308 Page:
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Kataoka Masako¹^ORCID,Honda Maya¹^ORCID

Affiliation:

1. From the Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-kawaharacho Sakyo-ku, Kyoto 606-8507 Japan (M.K.); and Department of Diagnostic Radiology, Kansai Electric Power Hospital, Osaka, Japan (M.H.).

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology, Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.231649

Reference10 articles.

1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

2. Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update

3. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

4. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low

5. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP